canakinumab
novartis
['nsclc', 'sclc', 'lba1 ']
 presents lba1 #esmo22 on the influence of pm2.5 pollutant on incidence of egfrm nsclc + therapeutic potential of canakimumab. a refreshing international collaborative piece integrating epidemiology and benchwork 
CRUK Clinical Research Fellow in Med Oncology and Early Phase trials @UCLcancer and @UCLH. Alma mater @Cambridge_Uni. Interested in GU, Lung, Ovarian Ca.